MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors

Core Insights - MiNK Therapeutics has published new preclinical data for MiNK-215, a next-generation CAR-iNKT therapy targeting FAP-positive cancer-associated fibroblasts to enhance antitumor immunity [1][4] - MiNK-215 is designed to overcome barriers in solid tumors by eliminating immunosuppressive stroma and enhancing immune activation through IL-15 secretion [2][3] Company Overview - MiNK Therapeutics is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune disorders [5] - The company aims to restore immune balance and drive durable cytotoxic responses through its proprietary iNKT platform [5] Product Details - MiNK-215 targets FAP-positive cancer-associated fibroblasts, which contribute to the immunosuppressive tumor microenvironment, thereby allowing immune cells to infiltrate and attack cancer cells [7][8] - The therapy is characterized as an "off-the-shelf" solution, enabling scalable manufacturing and immediate delivery for patients with solid tumors resistant to existing treatments [3][4] Preclinical Findings - MiNK-215 has shown the ability to remodel the tumor microenvironment, activate dendritic cells, and re-polarize macrophages to a pro-inflammatory state, enhancing immune response in preclinical models [8] - The therapy has demonstrated potent and lasting anti-tumor activity in models of lung and MSS colorectal cancer [7][8]